In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo | Annals of Internal Medicine
Source Citation Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916